Bessemer Group
GPCR icon

Bessemer Group’s Structure Therapeutics GPCR Stock Holding History

Bessemer Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29
Closed -$2K – 2582
2025
Q4 		$2K Hold
29
– – ﹤0.01% 2414
2025
Q3 		$1K Buy
+29
New +$578 ﹤0.01% 2412

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bessemer Group's GPCR Position: Q1 2026 in Review

Bessemer Group sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 29 shares — an estimated $2K sold.

Bessemer Group first reported a position in GPCR in Q3 2025 and held it in 2 quarters. The position peaked at $2K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Bessemer Group reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bessemer Group sold 29 Structure Therapeutics shares in Q1 2026, an estimated $2K.
  • Bessemer Group first reported a position in Structure Therapeutics in Q3 2025 and held it in 2 quarters.
  • Bessemer Group's Structure Therapeutics position peaked at $2K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.